Elegen and GSK sign a collaboration and licensing agreement to further develop Elegen's cell-free DNA production technology

January 24, 2024, 3697 characters

Elegen, a leading manufacturer of innovative DNA, today announced a collaboration and licensing agreement with GSK (LSE/NYSE: GSK), allowing the company to use Elegen's proprietary cell-free DNA manufacturing technology in the development of GSK's vaccines and medicines. .

The agreement includes upfront payments and purchase commitments from Elegens ENFINIA DNA to support GSK's development of pharmaceuticals and vaccines, including RNA vaccines. Elegen is also entitled to significant short-term payments related to the development of new product features as well as a potential equity investment from GSK in Elegen.

Launched in March last year, ENFINIA DNA delivers highly complex, high-quality, NGS-certified linear DNA of up to 7 kb in just seven business days. Unlike traditional synthesis of mRNA from linear plasmid DNA, Elegen's DNA is produced in a completely cell-free manner, enabling a seamless transition from discovery to clinical scale-up under good manufacturing practices. This technology can save significant time and resources spent on cloning, linearizing and purifying plasmid DNA, as well as establishing master cell banks. Elegen's innovation in cell-free DNA manufacturing technology represents a major advance that could advance the next generation of mRNA, cell and gene therapies.

This collaboration follows the early access program launched by Elegen in May last year, which offered DNA of greater length and complexity to selected customers. “Over the past year, dozens of customers, including many of the top 10 biopharmaceutical companies, have vouched for the unprecedented speed, length, precision and complexity of our cell-free DNA production technology,” said Dr. Matthew Hill, Founder and CEO of Elegen. “GSK recognizes the importance of a reliable and ready supply of DNA for a variety of applications where speed, accuracy and quality in DNA synthesis are critical. This collaboration will expand our offerings to include clinical production of genetic medicines, potentially including mRNA, cellular and viral gene therapies.”

About elegen

Elegen offers unique insights and technical innovations to produce high-quality synthetic DNA faster, catalyzing the next revolution in life sciences. The company is led by experienced leaders with decades of experience developing novel and scalable methods in molecular biology, chemistry and microfluidics. Elegen uses a proprietary microfluidic method to produce longer, higher-quality DNA in less time for the agricultural, chemical, healthcare and pharmaceutical industries. Founded in 2017, Elegen is a privately held company headquartered in the San Francisco Bay Area. For more information, please visit the website elegenbio.com And communicate with us LinkedIn And x (Twitter).

The source language in which the original text is published is the official and authorized version. Translations will be included for better understanding. Only the language version that was originally published is legally valid. Therefore, compare the translations with the original language version of the publication.

View the original on Businesswire.com: https://www.businesswire.com/news/home/20240124909422/de/

BSN Podcast

Christian Drastl: Vienna Stock Exchange Chat

Stocks on the radar:AT&S, Zumtobel, Andritz, Warempex, Amaj, Mobility Pierre, ATX Prime, ATX TR, ams-osram, Fig, Weinerberger, Uniqa, ATX, SBO, voestalpine, Bor, Bawaj, Mayer Mellenhof, OMV, Strabag, Marinomed Biotechnology, S Realty, compound, Adecco Bank, Rosenbauer, SW Environmental Technology, Oberbank AG Fund, semperite, Re Magnecita, Walford, We were tempted.

Random partners

---

Wolftank Adisa
Wolftank-Adisa Holding AG is the parent company of an international group of companies focused on the rehabilitation and monitoring of (large) tank systems and environmental protection services for contaminated soils and facilities.

>> Visit 68 other partners at boerse-social.com/partner